Vadodara-based Alembic pharmaceuticals has said that it has made a strategic investment in RIGImmune Inc., a biopharmaceutical research company co-founded by two prominent Yale University professors Dr. Anna Pyle and Dr. Akiko Iwasaki. RIGImmune, which is focusing on research and development of  ​​innate immunity and RNA based therapies for viral diseases and oncology applications by targeting the innate immune target, will utilize the proceeds of the series seed round to further the development of therapeutic oligonucleotides developed by Dr. Pyle and Dr. Iwasaki.